水通、水金组穴抑制舒芬太尼引起呛咳的临床观察

注册号:

Registration number:

ITMCTR2100005117

最近更新日期:

Date of Last Refreshed on:

2021-08-02

注册时间:

Date of Registration:

2021-08-02

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

水通、水金组穴抑制舒芬太尼引起呛咳的临床观察

Public title:

Clinical observation of shuitong and Shuijin points to inhibit sufentanil-induced cough

注册题目简写:

English Acronym:

研究课题的正式科学名称:

水通、水金组穴抑制舒芬太尼引起呛咳的临床观察

Scientific title:

Clinical observation of shuitong and Shuijin points to inhibit sufentanil-induced cough

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100049406 ; ChiMCTR2100005117

申请注册联系人:

许际平

研究负责人:

许际平

Applicant:

xu jiping

Study leader:

xu jiping

申请注册联系人电话:

Applicant telephone:

13792045179

研究负责人电话:

Study leader's telephone:

13792045179

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

rzhwfxjp@163.com

研究负责人电子邮件:

Study leader's E-mail:

rzhwfxjp@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

山东日照望海路66号

研究负责人通讯地址:

山东日照望海路66号

Applicant address:

66 Wanghai Road, Rizhao City,Shandong Province

Study leader's address:

66 Wanghai Road, Rizhao City,Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

日照市中心医院

Applicant's institution:

Rizhao Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2021-05

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

日照市中心医院伦理委员会

Name of the ethic committee:

Ethics committee of Rizhao Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021/7/22 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

日照市中心医院

Primary sponsor:

Rizhao Central Hospital

研究实施负责(组长)单位地址:

日照市望海路66号

Primary sponsor's address:

66 Wanghai Road, Rizhao City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

日照市

Country:

China

Province:

Shandong

City:

Rizhao

单位(医院):

日照市中心医院

具体地址:

日照市望海路66号

Institution
hospital:

Rizhao Central Hospital

Address:

66 Wanghai Road, Rizhao City

经费或物资来源:

自筹经费

Source(s) of funding:

Self financing

研究疾病:

舒芬太尼导致的并发症

研究疾病代码:

Target disease:

Complications from sufentanil

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

评价针刺水通、水金组穴预防全麻诱导期舒芬太尼诱发咳嗽反应的疗效。

Objectives of Study:

To evaluate the effect of acupuncture at shuitong point and Shuijin point on preventing cough response induced by sufentanil during general anesthesia induction.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

心、肺功能正常,无吸毒史,无长期应用阿片类药物史,耐受手术麻醉。

Inclusion criteria

Heart and lung functions were normal, no history of drug abuse, no history of long-term use of opioids, and tolerance to surgical anesthesia.

排除标准:

术前体温>38.5℃,术前近2周有上呼吸道感染病史,慢性阻塞性肺疾病,哮喘病史,胸科手术、高血压病史、吸烟、使用激素、支气管扩张药物、血管转化酶抑制剂

Exclusion criteria:

Preoperative temperature > 38.5℃, history of upper respiratory tract infection nearly 2 weeks before surgery,, chronic obstructive pulmonary disease, asthma, chest surgery, history of hypertension, smoking, use of hormones, bronchodilator drugs, vasoinvertase inhibitors

研究实施时间:

Study execute time:

From 2021-08-01

To      2021-11-01

征募观察对象时间:

Recruiting time:

From 2021-08-01

To      2021-11-01

干预措施:

Interventions:

组别:

D组

样本量:

50

Group:

group D

Sample size:

干预措施:

麻醉诱导前给予生理盐水2ml

干预措施代码:

Intervention:

2ml normal saline was injected intravenously before induction of anesthesia

Intervention code:

组别:

Z组

样本量:

50

Group:

group Z

Sample size:

干预措施:

麻醉诱导前针刺水通、水金穴

干预措施代码:

Intervention:

acupuncture at shuitong point and Shuijin point before induction of anesthesia

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

山东

市(区县):

日照

Country:

China

Province:

Shandong

City:

Rizhao

单位(医院):

日照市中心医院

单位级别:

三乙

Institution/hospital:

Rizhao Central Hospital

Level of the institution:

Tertiary Hospital

测量指标:

Outcomes:

指标中文名:

血流动力学的变化

指标类型:

次要指标

Outcome:

Changes in hemodynamics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呛咳例数

指标类型:

主要指标

Outcome:

Choking cough cases

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呛咳严重程度

指标类型:

主要指标

Outcome:

Severity of coughing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胸壁僵硬例数

指标类型:

次要指标

Outcome:

Number of chest wall stiffness cases

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 0
Min age years
最大 85
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由麻醉医师采用随机数字表法将100例患者分为两组

Randomization Procedure (please state who generates the random number sequence and by what method):

The anesthesiologist uses a random number table method to divide 100 patients into two groups

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表论文是共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Published in the form of an article

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统